How did you fare on your March Madness brackets? Did you win your EMG lab pool? Did you pick any upsets? Tune in and you will be sure to win this Lessons from the Lab March Madness bracket. It’s full of surprises and successes, and you won’t be “upset".

Enjoy this Valentine’s Day edition of Lessons From the Lab! Drs. Rubin and Levin work through a case with some twists and turns and a variety of teaching points – it’s just like not knowing what you are going to get when you open a box of Valentine’s Day chocolates!

Grab your hot chocolate and cozy up to your fireplace as you warm up with an educational discussion about a patient who lost his voice. Drs. Rubin and Munin will help teach you how to help patients find their voice (or at least find some muscles contributing to their voice with needle EMG) as they figure out the best way to approach this patient.

4/15/25- Advancing the Field: Perspectives from Nerve Conduction Technologists" In this podcast, host Carrie Ford interviews four nerve conduction technologists: Candy Dolan, Pati Ramsey, Nicole Wiley, and Nathaniel Dickey. They discuss how the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) transformed their field by establishing the Certified Nerve Conduction Technologist credential in 2011. The technologists share insights about AANEM membership benefits, certification challenges, employer support, and offer advice to newcomers on mentorship and continuous learning. All emphasize the importance of certification and community involvement in maintaining professional standards.  40 min

3/18/2025- The podcast explores the AANEM Training Program Partnership (TPP), an educational resource designed for neurology and PM&R training programs. The discussion features current neuromuscular fellows, Sukhraj Gill & Praveen Attele, along with hosts Bhaskar Roy (an associate professor at Yale) and Carrie Ford (a technologist at University of Utah).  16 min

1/30/2025-In this AANEM podcast, Dr. Stino interviews Dr. Allen on the groundbreaking ADHERE study, published in Lancet Neurology in 2024, which investigated efgartigimod for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). As the largest CIDP trial to date with 322 patients across 146 sites, it marked the first major study of a targeted biologic therapy in CIDP. The trial featured a unique two-stage design: an open-label response phase followed by a randomized controlled phase for responders. Dr. Allen explains the rationale behind targeting IgG in CIDP, despite its less clear antibody-mediated mechanism compared to myasthenia gravis. The study demonstrated a 66-70% response rate in the open-label phase, with significantly lower relapse rates compared to placebo in the randomized phase. This research represents a significant advancement in CIDP treatment options, offering a weekly subcutaneous administration that could reduce treatment burden compared to traditional therapies. 31 min.